分析
2026年9月4日•1分で読めます
Jongkundang Q2 Outlook Steady on Obesity Drug Wegobi; Profit Forecast Slightly Below Consensus
Analyst Huh Hyemin of Kiwoom Securities forecasts Jongkundang's Q2 sales at 4.629 trillion KRW, up 8% YoY, but operating profit at 193 billion KRW, 13% lower, slightly below consensus.
分析
2026年9月2日•1分で読めます
Pharmacy Association Faces Criticism Over Large-Pharmacy Bias in OTC Oral Contraceptive Discount Promotion
A discount program for OTC oral contraceptives requires pharmacies to buy 210+ units for the lowest price, a threshold many small pharmacies find unattainable, sparking controversy.
分析
2026年9月2日•1分で読めます
Yuhan Corp. drug business exceeds 1.4 trillion KRW in 2025 sales
Yuhan Corp. reports its drug segment reached 1.4 trillion KRW in 2025, a 3.5% YoY increase, driven by balanced growth of prescription and OTC products.
分析
2026年9月2日•1分で読めます
20‑s in Korea Prefer Olive Young for Vitamins, Pharmacies for Cold Medicine
A survey of Korean 20‑year‑olds shows they buy vitamins at health‑beauty stores like Olive Young and turn to pharmacies only for illness‑related medicines.
1
分析
2026年9月1日•1分で読めます
Samjin Pharma to Normalize HydraSec Supply After MFDS Pediatric Indication Withdrawal
Following MFDS removal of pediatric use for diacetyl hexyl smectite, demand shifted to HydraSec, causing shortages; Samjin Pharma expects supply normalization this week.
分析
2026年9月1日•1分で読めます
Pharmacy Compounding and OTC Sales Stabilize in Korea Week 27, Minor Declines in Key Categories
Compounding volumes held steady while OTC sales slipped slightly in Korea's week 27, with modest drops across cough, throat, pain and digestive product lines.
分析
2026年8月30日•1分で読めます
Pamgen Science launches first 8‑hour sustained vitamin B complex
Pamgen Science introduced ‘VitainB’, Korea’s first sustained‑release vitamin B complex, targeting the high‑dose vitamin market.
分析
2026年8月30日•1分で読めます
KBIOHealth‑backed Chungbuk Firms Secure $40.6M Talks at BIO USA 2026
Six biotech firms from Chungcheongbuk-do, supported by KBIOHealth, reported $40.59 million in export discussions and $1 million in investment talks at BIO USA 2026 in San Diego.
分析
2026年8月30日•1分で読めます
Taejeon Group Secures Exclusive Korean Distribution Rights for Metagenics Health Supplements
Taejeon Group has signed an exclusive distribution agreement with US health‑supplement brand Metagenics, aiming to launch its products to Korean pharmacists, healthcare professionals and consumers.
分析
2026年8月26日•1分で読めます
Korea Secures Enrylaze Supply as Alternative to Discontinued Erwinase for ALL & Lymphoma
Following the shutdown of Erwinase’s manufacturer, Korea’s Rare & Essential Medicines Center signed a contract for Enrylaze, restoring treatment continuity for acute lymphoblastic leukemia and lymphoma patients.